Laser-generated shockwaves enhance antibacterial activity against biofilms in vitro.
Bacterial biofilm formation within chronic wound beds, which provides an effective barrier against antibiotics, is a known cause of recalcitrant infections and a significant healthcare burden, often requiring repeated surgical debridements. Laser-generated shockwaves (LGS) is a novel, minimally invasive, and nonthermal modality for biofilm mechanical debridement which utilizes compressive stress waves, generated by photonic absorption in thin titanium films to mechanically disrupt the biofilm. Prior studies have demonstrated LGS monotherapy to be selectively efficacious for biofilm disruption and safe for host tissues. In this study, we sought to determine if LGS can enhance the antimicrobial activity and biofilm disruption capability of topical antibiotic therapy.



Staphylococcus epidermidis biofilms grown in vitro on glass were treated with topical gentamicin (31, 62, and 124 μg/ml) with and without LGS (n = 3-11/treatment group). Mechanical shockwaves were generated with a 1,064 nm Nd:YAG laser (laser fluence 110.14 mJ/mm2, pulse duration 5 ns, spot size 3 mm). Following a 24-hour incubation period, bacterial viability was assessed by determining the number of colony-forming units (CFU) via the Miles and Misra method. Residual biofilm bioburden was analyzed using the crystal violet biofilm assay.



With gentamicin monotherapy, CFU density (CFU/mm2) at 31, 62, and 124 μg/ml were (282 ± 84) × 104, (185 ± 34) × 104, and (113 ± 9) × 104, respectively. With LGS and gentamicin therapy, CFU density decreased to (170 ± 44) × 104, (89 ± 24) × 104, and (43 ± 3) × 104, respectively (P = 0.1704, 0.0302, and 0.0004 when compared with gentamicin alone). Biofilm burden as measured by the assay in the gentamicin 31, 62, and 124 μg/ml groups was reduced by 80%, 95%, and 98% when LGS was added (P = 0.0102, >0.0001, and 0.0001 for all groups when compared with gentamicin alone). Furthermore, samples treated with LGS saw an increase in susceptibility to gentamicin, in terms of reduced biofilm bioburden and CFU densities.



LGS enhances the efficacy of topical antibiotics in an in vitro model. This has significant implications for clinical applications in the management of chronic soft tissue infections and recalcitrant chronic rhinosinusitis. Lasers Surg. Med. 49:539-547, 2017. © 2017 Wiley Periodicals, Inc.
Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California (UCLA), Los Angeles, California.
William
W
Yao
Department of Head and Neck Surgery, UCLA Medical Center, Los Angeles, California.
Edward C
EC
Kuan
Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California (UCLA), Los Angeles, California.
Nathan C
NC
Francis
Department of Head and Neck Surgery, UCLA Medical Center, Los Angeles, California.
Maie A
MA
St John
Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California (UCLA), Los Angeles, California.
Warren S
WS
Grundfest
Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California (UCLA), Los Angeles, California.
Zachary D
ZD
Taylor
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D058491:Bacterial Load / Q000187:drug effects / Q000528:radiation effects; D018441:Biofilms / Q000254:growth & development / Q000528:radiation effects*; D005839:Gentamicins / Q000627:therapeutic use*; D019220:High-Energy Shock Waves; D053844:Lasers, Solid-State / Q000627:therapeutic use*; D013212:Staphylococcus epidermidis / Q000187:drug effects / Q000502:physiology / Q000528:radiation effects*
D000900:Anti-Bacterial Agents; D005839:Gentamicins
biofilm; chronic wound infections; laser-generated shockwaves; topical antibiotics